LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- UN Peace Ambassador Dr. Michael K. Obeng, the founder of Restore Worldwide, ...

As part of CMS’ movement to better healthcare, Sharecare aims to deliver immediate value to people through digital solutions that are secure, user-centered, and connected. Alongside other industry ...

Ecully, July 30, 2025 – 7 p.m. The Board of Directors of Spineway, meeting on July 30, 2025 under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, ...

SupplyCopia's participation at AHRMM25 builds on the company's continued commitment to transforming healthcare supply chains through innovative AI solutions. The company's technology has helped health ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep ...

The Canadian Red Cross extends its gratitude to Gary Slaight and The Slaight Family Foundation for a $1 million contribution over two years, in support of humanitarian efforts in Cox’s Bazar, ...

About BioNexus Gene Lab Corp. BGLC is an innovation-led life-sciences platform – bringing together precision diagnostics, cross-border expertise, and AI data development. Listed on Nasdaq, BGLC’s ...

VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs ...

Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD- (L)1 therapy ...

Avacta will hold an investor event shortly after the ESMO presentation. Further details will be made available nearer the time.

Preclinical data presented at SAWC, the largest wound care conference in the United States, highlighted the in vitro performance of revyve ®, including inhibition of key proteases such as matrix ...